科研之友
微信
新浪微博
Facebook
分享链接
摘要
Purpose To evaluate if the new Discovery Molecular Insights (DMI) PET/CT scanner provides equivalent results compared to the standard of care PET/CT scanners (GE Discovery 600 or GE Discovery 690) used in our clinic and to explore any possible differences in semi-quantitative measurements. Methods The local Institutional Review Board approved the protocol and written informed consent was obtained from each patient. Between September and November 2016, 50 patients underwent a single F-18-FDG injection and two scans: the clinical standard PET/CT followed immediately by the DMI PET/CT scan. We measured SUVmax and SUVmean of different background organs and up to four lesions per patient from data acquired using both scanners. Results DMI PET/CT identified all the 107 lesions detected by standard PET/CT scanners, as well as additional 37 areas of focal increased F-18-FDG uptake. The SUVmax values for all 107 lesions ranged 1.2 to 14.6 (mean +/- SD: 2.8 +/- 2.8), higher on DMI PET/CT compared with standard of care PET/CT. The mean lesion: aortic arch SUVmax ratio and mean lesion: liver SUVmax ratio were 0.2-15.2 (mean +/- SD: 3.2 +/- 2.6) and 0.2-8.5 (mean +/- SD: 1.9 +/- 1.4) respectively, higher on DMI PET/CT than standard PET/CT. These differences were statistically significant (P value < 0.0001) and not correlated to the delay in acquisition of DMI PET data (P < 0.0001). Conclusions Our study shows high performance of the new DMI PET/CT scanner. This may have a significant role in diagnosing and staging disease, as well as for assessing and monitoring responses to therapies.
- 出版日期2017-6-5
